{
    "nct_id": "NCT04592913",
    "official_title": "A Randomized, Double-blind, Placebo-controlled, Phase III Study of Neoadjuvant-Adjuvant Durvalumab and FLOT Chemotherapy Followed by Adjuvant Durvalumab in Patients With Resectable Gastric and Gastroesophageal Junction Cancer (GC/GEJC)",
    "inclusion_criteria": "* Patients with histologically documented gastric or gastroesophageal junction adenocarcinoma with resectable disease (Stage II or higher per AJCC 8th edition).\n* Patients must undergo radical surgery.\n* No prior anti-cancer therapy for the current malignancy.\n* World Health Organization (WHO)/ECOG performance status of 0 or 1 at enrollment.\n* Adequate organ and marrow function.\n* Availability of tumor sample prior to study entry.\n* Must have a life expectancy of at least 24 weeks.\n\nKey\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 200 Years",
    "exclusion_criteria": "* Patients with peritoneal dissemination or distant metastasis.\n* Patients with adenosquamous cell carcinoma, squamous cell carcinoma, or GI stromal tumor.\n* Current or prior use of immunosuppressive medication within 14 days before the first dose of durvalumab.\n* Contra-indication to any of the study drugs.\n* History of allogeneic organ transplantation.",
    "miscellaneous_criteria": "Key"
}